AAP Implantate: Balanced EBITDA in H1, Trauma Segment Turns Positive

• Sales for H1/2024 increased by 10% to EUR 6.4 million compared to H1/2023, with the EMEA region being the main growth driver.
• EBITDA for H1/2024 broke even at EUR -0.0 million, showing significant improvement from EUR -1.0 million in H1/2023, largely due to increased sales and reduced costs.
• The trauma business achieved a positive EBITDA, contributing to the overall financial improvement of the company.
• Operating cash flow improved by 34% year-on-year to EUR -1.0 million, primarily due to better operating results.
• The company expects revenue for the second half of 2024 to match the first half, aiming for a total revenue of EUR 11.5 million to EUR 13.5 million for the full year.
• Future risks include potential sanctions against Russia, rising energy prices, and recession-related financial impacts, which could affect the company's operations and financial stability.

The price of aap Implantate at the time of the news was 1,1450EUR and was down -0,43 % compared with the previous day.

aap Implantate

-2,46 %

-1,65 %

+12,26 %

-0,83 %

+36,78 %

-70,22 %

-85,52 %

-95,04 %

-85,93 %

ISIN:DE000A3H2101WKN:A3H210

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max